FSFrancesco Segrado

Francesco Segrado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Segrado has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze–thaw stability

    by Lara Pattaroni, Elisabetta Venturelli, Daniele Morelli, Michela Bianchi, Giulia Guerra, Francesco Segrado, Sabina Sieri, Alessio Polymeropoulos, Claudia Agnoli

    Background: Chronic inflammation from visceral obesity contributes to metabolic disorders and cancer through cytokine imbalance. Accurate cytokine measurement is crucial to understand these links. This study examined challenges in quantifying interleudin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), leptin, and adiponectin in historical biobank samples with limited volumes and varying plasma anticoagulants. Methods: Luminex-MAGPIX platform was used to evaluate three analytical aspects. Single-well precision was assessed via intra- and inter-assay coefficients of variability (CVs). Plasma matrix effects were examined by pairwise comparison of analyte concentrations across citrate, heparin, and EDTA plasma from 10 volunteers. Cytokine stability was tested after one freeze-thaw cycle (analysis of variance). Results: Single-well measurements showed good precision (CV <10% intra-assay, <15% inter-assay). Plasma matrix affected absolute concentrations. In particular, all analytes were lower in citrate than in EDTA and heparin, but relative relationships and subject-specific rankings remained preserved. Pearson correlation coefficients for IL-6, leptin, and adiponectin were high across matrices (r-range = 0.952–0.999), whereas correlations for TNF-α were lower (r-range = 0.897–0.972). Freeze–thaw stability was analyte- and matrix-dependent: leptin remained stable in heparin and EDTA but decreased 9.5% in citrate; adiponectin was stable in citrate but decreased in heparin (−9.0%) and EDTA (−11.8%). IL-6 and TNF-α were unaffected. Conclusion: IL-6, TNF-α, leptin, and adiponectin were accurately quantified using single-well Luminex assays and showed reasonable tolerance to a single freeze–thaw cycle, offering a practical strategy for preserving valuable specimens. Although plasma anticoagulant affected absolute concentrations, the preservation of relative analyte rankings permits their use in most study designs but limit absolute value comparisons.


  • Open Access

    Investigating Variability in Metabolomics: A Comparative Study of Analytical Platforms and Blood Matrices Using HPLC-HRMS

    by Giulia Guerra, Alessio Polymeropoulos, Elisabetta Venturelli, Veronica Huber, Francesco Segrado, Daniele Morelli, Sabina Sieri

    Untargeted metabolomics faces significant challenges in standardization due to variability introduced by sample preparation and analytical workflows. We systematically evaluated the impact of biological matrices, extraction protocols, and chromatographic configurations to establish a mechanism-informed framework aimed at improving reproducibility in large-scale clinical and epidemiological studies. Three extraction protocols were compared using an in-house pooled heparin plasma: monophasic protein precipitation with isopropanol (IPA), methanol:acetonitrile (MeOH:ACN), and a modified Matyash biphasic method. The most reproducible protocol was then applied to four blood matrices. Samples were analysed using untargeted metabolomics on hydrophilic interaction liquid chromatography (HILIC) and reversed-phase (RP) HPLC columns, with mass spectrometry data processed using Compound Discoverer. Both IPA and MeOH:ACN extractions achieved over 80% of features with coefficient of variation (CV%) ≤ 30% for both RP and HILIC, whereas the Matyash method showed higher variability, with a larger proportion of metabolites exhibiting CV% > 30%. Across matrices, RP chromatography detected over 80% of metabolites with CV% < 30%, while HILIC showed higher variability, with at least 20% of metabolites above this threshold. Among matrices, serum and heparin plasma outperformed EDTA and citrate in reproducibility. We propose a standardized workflow in which monophasic extractions combined with RP chromatography maximize reproducibility and metabolite coverage, minimizing methodological artefacts and providing a reliable framework for robust biological discovery in large-scale untargeted metabolomics studies.


  • Open Access

    Supplementary Figure from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort

    by Valeria Pala, Claudia Agnoli, Adalberto Cavalleri, Sabina Rinaldi, Rosaria Orlandi, Francesco Segrado, Elisabetta Venturelli, Marco Vinceti, Vittorio Krogh, Sabina Sieri

    Supplementary Figure from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort

  • Open Access

    Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort

    by Valeria Pala, Claudia Agnoli, Adalberto Cavalleri, Sabina Rinaldi, Rosaria Orlandi, Francesco Segrado, Elisabetta Venturelli, Marco Vinceti, Vittorio Krogh, Sabina Sieri

    Background:Case–control studies show that copper (Cu) is high and zinc (Zn) low in blood and urine of women with breast cancer compared with controls.Methods:To assess whether prediagnostic Cu and Zn are associated with breast cancer risk, OR of breast cancer according to Cu, Zn, and Cu/Zn ratio in plasma and urine was estimated in a nested case–control study within the ORDET cohort, using conditional logistic regression adjusted for multiple variables: First 496 breast cancer cases and matched controls, diagnosed ≥2 years after recruitment (to eliminate reverse causation) were analyzed. Then all eligible cases/controls were analyzed with stratification into years from recruitment to diagnosis.Results:For women diagnosed ≥2 years, compared with lowest tertiles, breast cancer risk was higher in the highest tertile of plasma Cu/Zn ratio (OR, 1.75; 95% CI, 1.21–2.54) and the highest tertile of both plasma and urine Cu/Zn ratio (OR, 2.37; 95% CI, 1.32–4.25). Risk did not vary with ER/PR/HER2 status. For women diagnosed <2 years, high Cu/Zn ratio was strongly associated with breast cancer risk.Conclusions:Our prospective findings suggest that increased Cu/Zn ratio in plasma and urine may be both an early marker of, and a risk factor for, breast cancer development. Further studies are justified to confirm or otherwise our results and to investigate mechanisms.Impact:Our finding that prediagnostic Cu/Zn ratio is a strong risk factor for breast cancer development deserves further investigation and, if confirmed, might open the way to interventions to reduce breast cancer risk in women with disrupted Cu/Zn homeostasis.

  • Open Access

    Supplementary Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort

    by Valeria Pala, Claudia Agnoli, Adalberto Cavalleri, Sabina Rinaldi, Rosaria Orlandi, Francesco Segrado, Elisabetta Venturelli, Marco Vinceti, Vittorio Krogh, Sabina Sieri

    Supplementary Data from Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort

  • Open Access

    Explorative Detection of Fractional Exhaled Nitric Oxide ( FeNO ) in Exhaled Breath of Patients With Breast Cancer

    by Francesco Segrado, Alessio Polymeropoulos, Michela Bianchi, Chiara Veronese, Roberto Agresti, Gianfranco Scaperrotta, Roberto Boffi, Rosalba Miceli, Rosaria Orlandi

    Background: Nitric oxide (NO), a gaseous messenger with pleiotropic functions, plays a role in cancer, including breast cancer (BC). Considering the high permeability and leakiness of NO across tissues and the increased levels of NO recently reported in exhaled breath and blood of patients with lung cancer, we explored exhaled NO levels in patients with BC in a future perspective of non‐invasive cancer detection. Patients and Methods: Fractional exhaled NO (FeNO) levels were detected in the breath of 192 women with BC and malignancy‐free controls employing a widely used point‐of‐care (POC)‐based system previously developed for asthma monitoring. Results: FeNO levels were lower in BC patients compared to controls, with the lowest levels in women with HER2‐expressing tumors. In univariate and multivariate analyses and after adjustment for age, smoking, and asthma, this difference was not significant. The effects of smoking were not statistically significant, whereas asthmatic subjects had significantly higher levels of FeNO ( p = 0.006). Neither menopause nor BMI had a significant impact on FeNO levels. Conclusion: Our explorative work indicates that FeNO levels are heterogeneously detected in the breath of BC patients in the absence of confounding effects and are associated with the clinical characteristics of the disease. More sensitive detection of exhaled NO and larger cohorts enriched with ER negative BC are needed to further explore the potential of NO in non‐invasive detection of BC, either alone or in conjunction with other BC‐related volatile markers, and extending the NO measurement to blood or tissues.


  • Comprehensive assessment of matrix effects in metallomics: Evaluating 27 metals in serum, heparine-plasma-, EDTA-plasma and citrate-plasma by ICP-MS analysis

    by Giulia Guerra, Elisabetta Venturelli, Alessio Polymeropoulos, Francesco Segrado, Daniele Morelli, Sabina Rinaldi, Claudia Agnoli, Sabina Sieri


  • Changes in the Volatome of Cancer Patients

    by Francesco Segrado, Andrea Romano, Rosaria Orlandi


  • Open Access

    A software-assisted untargeted liquid chromatography–mass spectrometry method for lipidomic profiling of human plasma samples

    by Francesco Segrado, Adalberto Cavalleri, Alice Cantalupi, Luigi Mariani, Sonia Dagnino, Vittorio Krogh, Elisabetta Venturelli, Claudia Agnoli

    Introduction: In this paper, an analytical pipeline designed for untargeted lipidomic profiling in human plasma is proposed. The analytical pipeline was developed for case-control studies nested in prospective cohorts. Methods: The procedure consisted of isopropanol protein precipitation followed by reverse phase liquid chromatography coupled to high resolution mass spectrometry and software-assisted data processing. The compounds are putatively annotated by matching experimental mass spectrometry data with spectral library data using LipidSearch software. The lipid profile of a pool of plasma samples from 10 healthy volunteers was detected in both positive and negative polarity modes. The impact of the chosen polarity on the number and quality of the lipid identification has been evaluated. Results: More than 1000 lipids from 12 different classes were detected, 1150 in positive mode and 273 in negative mode. Nearly half of them were unambiguously identified by the software in positive mode, and about one-third in negative mode. The method repeatability was assessed on the plasma pool samples by means of variance components analysis. The intra- and inter-assay precision was measured for 10 lipids chosen among the most abundant found within the different lipid classes. The intra-assay coefficients of variation ranged from 2.56% to 4.56% while intra- and inter-day coefficients of variance never exceeded the 15% benchmark adopted. The lipidomic profiles of the 10 healthy volunteers were also investigated. Discussion: This method detects a wide range of lipids and reports their degree of identification. It is particularly fit and well-designed for large case-control epidemiologic studies.


  • Open Access

    Prediagnostic Levels of Copper and Zinc and Breast Cancer Risk in the ORDET Cohort

    by Valeria Pala, Claudia Agnoli, Adalberto Cavalleri, Sabina Rinaldi, Rosaria Orlandi, Francesco Segrado, Elisabetta Venturelli, Marco Vinceti, Vittorio Krogh, Sabina Sieri

    Background: Case–control studies show that copper (Cu) is high and zinc (Zn) low in blood and urine of women with breast cancer compared with controls. Methods: To assess whether prediagnostic Cu and Zn are associated with breast cancer risk, OR of breast cancer according to Cu, Zn, and Cu/Zn ratio in plasma and urine was estimated in a nested case–control study within the ORDET cohort, using conditional logistic regression adjusted for multiple variables: First 496 breast cancer cases and matched controls, diagnosed ≥2 years after recruitment (to eliminate reverse causation) were analyzed. Then all eligible cases/controls were analyzed with stratification into years from recruitment to diagnosis. Results: For women diagnosed ≥2 years, compared with lowest tertiles, breast cancer risk was higher in the highest tertile of plasma Cu/Zn ratio (OR, 1.75; 95% CI, 1.21–2.54) and the highest tertile of both plasma and urine Cu/Zn ratio (OR, 2.37; 95% CI, 1.32–4.25). Risk did not vary with ER/PR/HER2 status. For women diagnosed <2 years, high Cu/Zn ratio was strongly associated with breast cancer risk. Conclusions: Our prospective findings suggest that increased Cu/Zn ratio in plasma and urine may be both an early marker of, and a risk factor for, breast cancer development. Further studies are justified to confirm or otherwise our results and to investigate mechanisms. Impact: Our finding that prediagnostic Cu/Zn ratio is a strong risk factor for breast cancer development deserves further investigation and, if confirmed, might open the way to interventions to reduce breast cancer risk in women with disrupted Cu/Zn homeostasis.